Friday, August 11, 2023
Hikma Pharmaceuticals announces an exclusive licensing and commercialisation agreement with Rakuten Medical.
Under this agreement, Hikma Pharmaceuticals has secured the exclusive rights to commercialize products in Rakuten Medical's pipeline that utilize the Alluminox™ platform across the Middle East and North Africa (MENA) markets. This collaboration brings together the strengths of both companies to develop and deliver cutting-edge cancer therapies to patients in the MENA region.
This partnership between Hikma Pharmaceuticals and Rakuten Medical holds immense promise for advancing cancer treatments. By collaborating on this transformative technology, they aim to improve the lives of cancer patients in the MENA region, providing them with access to innovative therapies and better health prospects.
The Alluminox™ platform is an investigational technology that revolves around photoimmunotherapy, a cancer treatment approach. The platform's drug component involves a targeting moiety combined with specialized dyes that facilitate selective binding to cell surfaces.
The device component of the platform includes a light source designed to illuminate the targeted cells with light. This light activation leads to the temporary activation of the drug, enabling a localized therapeutic effect.
